

Transitioning from Intravenous Infusion to Subcutaneous Injection: A Seamless Patient Experience


Discover how IQVIA's flexible patient support services helped rheumatoid arthritis patients transition from intravenous to subcutaneous formulation.



For the best user experience, please open this infographic using Google Chrome or Adobe Acrobat

Situation

During the COVID-19 pandemic, a large pharmaceutical company wanted to move as many rheumatoid arthritis patients as possible to a different treatment formulation.



Solution

IQVIA offered a 4-month patient support programme to ensure a smooth transition.


Results


IQVIA's patient support programme helped rheumatoid arthritis patients transition to a different treatment formulation.



The project was extended by 3 months.

The **speed** of this project set up improved IQVIA's working relationship with the NHMC.





Patient referrals by month

not suitable or did not want to transfer to SC.